EXPIRED
PA-19-052 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
PA-19-053 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
PA-19-054 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
PA-19-092 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
PA-19-055 - NIH Research Project Grant (Parent R01 Clinical Trial Required)
PA-19-056 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
PA-19-091 - NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
National Institute on Drug Abuse (NIDA)
The National Institute on Drug Abuse is issuing this Notice to highlight its interest in preclinical and clinical research to advance the understanding of the effects of concomitant use of opioids and stimulants. The use of opioids, such as heroin and fentanyl, together with stimulants, such as methamphetamine and cocaine, is increasing; and deaths attributed to using these combinations are likewise increasing (Al-Tayyib et al., 2017; Jones et al, 2019; LaRue et al., 2019). Opioid overdose causes asphyxiation due to respiratory depression and stimulant overdose causes agitation, hyperthermia, and cardiac events due to sympathetic stimulation; however, the effects of their concomitant use have not been adequately characterized. Treatment of overdose of opioid-stimulant combinations is currently based on symptoms. Studies in animals and cell culture have demonstrated that exposure to an opioid and methamphetamine together can be more toxic than either drug alone (Namiki et al., 2005; Tian et al., 2017). However, the mechanisms underlying the potentially enhanced toxicity of the combination remain unknown. Identifying how opioids and stimulants interact in combination to produce increased toxicity will enhance our ability to develop medications to prevent and treat comorbid opioid and stimulant use disorders and overdoses associatedwith this combination of drugs.
Research Objectives
Areas of programmatic interest to NIDA include, but are not limited to:
Application and Submission Information
This notice applies to due dates on or after June 5, 2020 and subsequent receipt dates through September 8, 2023.
Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.
PA-19-052 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
PA-19-053 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
PA-19-054 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
PA-19-092 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
PA-19-055 - NIH Research Project Grant (Parent R01 Clinical Trial Required)
PA-19-056 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
PA-19-091 - NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:
Scientific/Research Contact(s)
National Institute on Drug Abuse / Division of Therapeutics and Medical Consequences
Telephone: 301-827-5918
Email: nappel@nih.gov
National Institute on Drug Abuse / Division of Therapeutics and Medical Consequences
Telephone: 301-827-5815
Email: katrina.foster@nih.gov
National Institute on Drug Abuse / Division of Neuroscience and Behavior
Telephone: 301-827-7376
Email: holly.moore@nih.gov